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Summary 
Aim  
We set out to determine the potential contribution of community pharmacists to improve the 
transfer of care of patients from secondary to primary care settings.  
Method  
We systematically reviewed the literature on interventions that involved community pharmacy post 
discharge. We considered all relevant studies, including both randomised and non-randomised 
controlled trials, irrespective of patient population. Our primary outcome was any impact on patient 
and medication outcomes, while the secondary outcome was to identify intervention characteristics 
that influenced all reported outcomes. 
Results  
We retrieved 14 studies that met our inclusion criteria. There were four studies reporting outcomes 
relating to the identification and rectification of medication errors that were significantly improved 
with community pharmacy involvement. Other patient outcomes such as medication adherence and 
clinical control were not unanimously positively or negatively influenced via the inclusion of 
community pharmacy in a transfer of care post discharge intervention. Some inconsistencies in 
implementation and process evaluation of interventions were found across the reviewed studies; 
this limited the accuracy with which true impact could be considered. 
Conclusions  
There is evidence that interventions including a community pharmacist can improve drug related 
problems after discharge, however, impact on other outcomes is not consistent. Further studies are 
required which include process evaluations to fully describe the context of the intervention so as to 
better determine any influencing factors. Also applying more stringent controls and closer 
adherence to protocols in both intervention and control groups would allow clearer correlations to 
be made between the intervention and the outcomes. 
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Introduction 
The transition of patients from primary to secondary care settings (and vice versa) is historically 
acknowledged as risky. Twenty percent of patients have been reported to experience adverse events 
within three weeks of discharge, 60% of which could have been ameliorated or avoided [1]. Patients 
are exposed to errors, which can have a detrimental effect on their health, recovery and overall 
satisfaction with the healthcare system [2,3]. 
Patients are often departing from a confusing and hectic discharge environment, supplied with 
messages about medicines management, follow-up appointments and other post-discharge 
information. The process is vulnerable to misunderstanding and miscommunication, often leaving 
the patient, carers and families ill-prepared to appropriately manage their care during the transition 
home [3,4]. Only 10% of elderly patients will be discharged on the same medication that they were 
admitted to hospital on [5]. Sixty percent of patients will have three or more medicines changed 
during their hospital stay [6]; 28-40% of medications are stopped within hospital, and 45% of 
medicines prescribed at discharge are new [7]. 
Pharmacists can potentially play a key role in patient care, especially at these transitions [8]. Indeed, 
the Royal Pharmaceutical Society of Great Britain (RPSGB) in 1992 advocated that hospital 
pharmacists should produce documentation for patients on discharge so as to assist with 
communication when they leave one healthcare setting and enter another [9]. The restructuring of 
the NHS in England, with the introduction of Clinical Commissioning Groups (CCGs) and their support 
and encouragement for new health care providers, has re-emphasised the important role the 
pharmacist can play in these transitions [10]. The working party responsible for the RPSGB report 
recommends fostering links within the community between pharmacists, clinicians, nurse, etc., so as 
to ensure patient needs are met when they move between healthcare settings [11]. Community 
pharmacists can offer accessibility, expertise in therapeutics, face-to-face contact and skills in drug 
problems and adherence [10,12]. A recent report from the Royal Pharmaceutical Society (RPS) 
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(previously RPSGB), ‘Keeping patients safe when they transfer between care providers – getting the 
medicines right’ (June 2012), provides guidance on the medicine information that should accompany 
a patient from one care setting to another [13]. Early adopter sites of this guidance piloted and 
trialled various interventions and services, many of which involved a role for community pharmacy. 
The adopting hospitals recognised the contribution of community pharmacies and begun referring 
patients for a Medicines Use Review (MUR) or New Medicines Service (NMS) consultation post-
discharge [14]. Urban and colleagues [15] summarise that poor communication to community 
pharmacists at discharge can cause unintended medication discrepancies and hinder continuity. 
They further promote the provision of consistent and timely communication to community 
pharmacy post discharge to ensure seamless transition and reduction in adverse issues.  
Although much literature has been published on the positive input of hospital pharmacists on 
admission and during discharge [4, 16, 17], less is known about their community counterparts and 
the effects of their interventions on patient outcomes. The RPS report [13] which recommended the 
improvement of communication during patient transfer and the increasing recognition and evidence 
of the clinical skills of community pharmacists, should lead to an increase in more clinical services 
being provided and commissioned within the community. 
Some studies have restricted the interventions of interest to medicines reconciliation or medication 
review, and have limited the population to, for example, those suffering from heart failure [18]. 
Others have investigated the potential of post-discharge (PD) community pharmacy interventions to 
improve continuity of care [2, 8, 19-22]. 
We therefore aim to systematically evaluate and quantify the effects of community pharmacy 
interventions on all potential outcomes of patients of all demographics and conditions discharged 
from hospital and considered to be at a point of transition. 
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Methods 
Searching  
The Cochrane Collaboration glossary of terms and the University of York guidelines for the conduct 
of systematic reviews and search strategies were consulted to frame the search. The included key 
points of research reporting, as specific in the Consolidated Standards of Reporting Trials (CONSORT) 
guidelines [23] for the publication of research describing RCTs, was utilised to assess the clarity of 
reporting in the included studies. Our search strategy identified research on interventions made or 
contributed by community pharmacies after hospital discharge. The following electronic databases 
were searched to identify evidence: MEDLINE, EMBASE, CINAHL, NHS EED, Cochrane Controlled 
Trials Register, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of 
Effects (DARE) and Web of Science. Trial registers and websites of funding organisations were 
searched for ongoing studies. On-line search of The Pharmaceutical Journal as well as hand searches 
of relevant conference abstracts (such as the RPS conferences) were conducted. Hand searches 
through reference lists of key articles was also undertaken and relevant information on unpublished 
and in-progress research from key-experts in the field was requested and included. 
Key words and synonyms used in the electronic search to frame the setting or aim of healthcare 
provision included: continuity of care, continuous care, continuum of care, seamless care, barriers to 
care, and ongoing care. Word derivatives for interventionists included: pharmacist, pharmacy, 
pharmacies, community pharmacy, pharmacy services and pharmacy practice. The search filters 
used were: randomised controlled trials; controlled clinical trials, random allocation, single-blind 
method, clinical trials, crossover trials and placebos.  
Study selection 
All titles retrieved via literature search were reviewed by one of the authors (HN) for relevance. Two 
of the authors (HN and ZN) then independently assessed the abstracts of these papers against the 
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inclusion criteria. The studies were delineated by their reported population/patient, intervention, 
control, and outcomes and included: (i) the population of patients which were identified as post-
discharge; (ii) intervention involved a community pharmacist or member of the community 
pharmacy team; (iii) intervention focussed on continuity of care, transfer of care or follow-up care; 
(iv) intervention occurred post-discharge from a hospital setting; (v) controlled trials that were 
randomised or non-randomised; (v) all reported outcomes were of interest. Papers were not 
excluded on the basis of language, country of origin or publication date. Full papers from those 
abstracts that were considered relevant were requested and assessed independently by the two 
authors for their suitability for inclusion and differences resolved by discussion with reference to a 
third reviewer (AT) if necessary. 
Validity assessment 
Validity assessment was guided by criteria recommended by Cochrane for assessing methodological 
quality [24]. Blinding of the assessors was not considered specifically relevant to the end-points of 
the studies; we therefore critiqued studies for potential influence of bias or confounding factors 
impacting on reported outcomes. We compared baseline characteristics of groups, and reported 
whether the studies described the clear and transparent flow of patients and why, if any, losses or 
drop-outs occurred. We also clearly defined primary and secondary outcomes, and provided a 
sample size calculation. We reported whether >80% of patients were retained in the trial, as well as 
any training that the pharmacists received or resources they required for the intervention. Two 
authors (HN and ZN) independently carried out this analysis and any discrepancies were resolved 
through discussion with the third author (AT). The appraisal will be used for descriptive purposes 
and will also highlight variations between studies. 
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Data abstraction 
Data were extracted on a piloted data extraction form adapted from an established Cochrane 
version. Two authors (HN and ZN) extracted data independently and checked for agreement or 
discrepancies. The third author (AT) was consulted for additional review where appropriate. Data 
included type of participants, intervention details, outcomes and trial quality characteristics. 
Study characteristics 
Classification of interventions: Interventions had to be delivered by a community pharmacist or 
member of the community pharmacy team. Singular or multiple interventions made by other 
healthcare professionals only (excluding community pharmacies post-discharge) were excluded. All 
forms of intervention made PD from a hospital setting were considered. All populations of patients 
were considered irrespective of their age, clinical condition or diagnosis, etc. All subsequent 
outcomes from interventions were considered including ‘soft’, e.g., patient satisfaction, medication 
adherence, and ‘hard’, e.g., clinical test results, mortality. Studies were categorised by: type of 
patient population; intervention components; funding/resources required for intervention; 
intervention preference compared to control. Interventions were classified according to the system 
reported and utilised by Hesselink and colleagues [1]. Contributing elements and examples of 
activities are described in Table 1. 
Outcomes: Due to heterogeneity in outcomes measured, all outcomes have been considered and 
reported. Outcome data were extracted at the study’s pre-specified last follow-up point. Formal 
pooling for meta-analysis was not possible due to the diversity of outcomes and scales employed, 
but informal pooling highlights were studies showed a significant positive, non-significant positive, 
negative or no effect. 
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Results 
Search results and study characteristics 
A total of 1,528 titles were identified from our literature search, which yielded 144 potentially 
relevant studies. Further assessment of the abstracts of these studies and hand searches led to a 
total of 14 controlled trials identified that fit the inclusion criteria for the review. Figure 1 describes 
the steps involved in the search and selection process.   
Studies are described by their nature, location and patient cohort, which were included as shown in 
Table 2. 
Study validity  
Six of the studies reported some statistical differences in baseline characteristics between their 
intervention and control groups [25-27, 30, 35]. The majority (n=10) of studies clearly described the 
patient flow, and where and why losses or drop-out occurred [19, 25, 26, 29-33, 36, 37]. In most of 
these studies, the retention rate was > 80%. However, one study did not include a flow diagram [28], 
but made reference to the previously reported trial [29], and another trial was reported as an 
abstract so lacked much of the required information for quality assessment [34]. Sample size 
calculations were reported in 64% of studies (n=9/14) [25, 26, 28, 30, 31, 33, 35-37], but only half 
achieved their required quota [25, 26, 28, 31]. All studies clearly defined their primary and/or 
secondary outcomes, and stipulated as and when specific resources or funding was utilised in the 
implementation of the interventions. 
Interventions 
Table 3 outlines the key characteristics of the individual interventions. This includes the year the 
study was published, the healthcare professional involved (e.g., hospital pharmacist), and the 
classification of the intervention (e.g., information, coordination, communication). Two of the 
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Australian studies reported on interventions delivered by a pharmacist belonging to the Home 
Medicine Review (HMR) programme [25, 26]. This Programme provided governmental remuneration 
for appropriately accredited pharmacists, who are generally based in community pharmacies, to 
carry out home visits to review medication and provide education and counselling. In these studies, 
the pharmacists had to undertake additional training in the area of warfarin therapeutics and patient 
education. In another group of related studies, pharmacists with a postgraduate qualification or 
recent continued professional development in therapeutics also had to receive additional training in 
heart failure, drugs used, exercise, diet, smoking cessation and communication skills [28, 29, 32]. 
Two studies ensured pharmacists received training on the use of the intervention protocol [33,36], 
and two studies involved reimbursement for pharmacists participating in the trial [31,36]. One study 
in USA only considered pharmacists providing services within CommUnity Care health centres, which 
specifically provide services to the medically underserved [30]. The remaining Australian study made 
use of a transition pharmacist (TP) who coordinated the medication communication transfer to 
primary care, community pharmacy and GP [30]. Only four trials reported utilising existing 
pharmacist roles, with no further training or funding deemed necessary [19, 27, 34, 37].  The 
majority of the interventions (n=9) involved the community pharmacist making a home visit [25-30, 
32, 33, 35], one involved telephonic communication [36], one was face-to-face interaction in the 
community pharmacy [31], and three were unclear to the authors as they were not described in 
detail [19, 34, 37]. These different forms of communication and interaction were performed in order 
to carry out a follow-up interview to provide education, counselling, check adherence and 
medication issues, remove inappropriate/excess medications and provide information on laboratory 
monitoring. Both primary and secondary outcomes measured were diverse, often with different 
measuring scales and in the majority of cases showing little agreement amongst studies (Table 2). Of 
the ten studies whose interventions involved increased information sharing between providers; 
improved coordination of care and improved communication, seven showed some statistically 
significantly positive outcomes. 
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Outcomes 
Only the outcomes that resulted from identification and rectification of drug reported problems 
received unanimous statistically significant positive effects with the intervention(s) and were seen in 
more than one study (n=4). Each of these studies described interventions that focus specifically on 
identifying and rectifying drug related problems; three of them [19, 27, 37] included sufficient detail 
to demonstrate that the interventions included activities from all key influential elements to 
improve safety and quality of transferring between settings (Table 3). In these studies, there was 
also a reported increase in the information transferred from hospital to pharmacy to facilitate the 
checking and monitoring of drug histories and discrepancies. This in turn helped increase the 
likelihood of meetings being arranged between community pharmacists and the respective patients 
to discuss medication issues. There was also increased communication between the care settings to 
organise a follow-up visit or review as the patient makes the transition. The remaining study 
reported significant improvements in drug related outcomes [34], possibly due to the increased 
coordination of pharmacist-led medication reviews. Table 4 provides further details on the outcomes 
reported for each study and the positive, negative and lack of statistically significant results. Of the 
key primary outcomes, such as hospital readmissions, mortality, patient medication adherence and 
the wider outcomes of quality of life and patient satisfaction, there was either no significant 
difference awarded with the intervention or little agreement between trials. As a consequence, 
these studies do not collectively evidence that the implemented interventions achieved any other 
statistically significant successful outcome in the intervention arm compared to the control. The 
factor of reimbursement or additional pharmacist support (either via a liaison pharmacist or 
specialist training in the intervention) did not contribute to improved trial outcomes across the 
studies. We found no population group characteristic was associated with significantly improved trial 
outcomes. However, six of the nine interventions that incorporated the three recognised 
characteristics of information sharing, coordination of care and communication did demonstrate 
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some outcomes classified as statistically significant, which suggests the importance of these 
particular factors in the design and delivery of interventions to improve transfer of care. 
Discussion 
Main study findings 
This work has indicated there is a role to be played by community pharmacists in improving the 
transfer of care for post-discharged patients. The particular outcome that has been demonstrated to 
be most successfully achieved is that of identification and rectification of drug related problems. The 
interventions in these particular studies were clearly designed to impact a focussed outcome, e.g. 
drug related problems, and protocols were appropriately structured and adhered to.  However, due 
to the design and implementation of many of the remaining studies, the full potential of the 
interventions may not have been fully appreciated. Most authors described the limitations to their 
studies (Table 5) and provided an opportunity for those planning a future intervention to reflect 
upon the design and delivery of their interventions, the evaluation methodology, data collection and 
analysis so as to avoid such impingements on possible future outcomes. 
The evidence here also suggests a need for randomised controlled trials that have a more stringent 
outline for the control rather than comparison to uncontrolled ‘usual care’. Caution should be 
heeded to regulate and account for activities that can take place in the control group that have 
characteristics similar to the intervention and can impact on subsequent outcomes reducing 
potential differences between the groups. Protocol violations also need to be minimised to ensure 
standardised delivery of the intervention and allow for subsequent accurate evaluation of outcomes. 
Thompson and Schoenfeld [38] deliberated over the use of usual care as a comparator to an 
intervention group. They recognised the need to acknowledge that usual care, in the absence of 
randomised controlled trials, is the safety standard. However, they then highlighted that the 
unstandardised nature of this comparator group runs the risk of merging with the intervention 
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during the trial and reducing differences between groups. Meaningful difference then becomes 
harder to deduce. They discussed how the use of usual care in a two-armed randomised controlled 
trial is appropriate for drug and devices and for non-pharmacological interventions that lie well 
outside of usual care practices. Adhering to these principles improves the investigation and 
deduction of findings regarding impact through the minimisation of confounding factors. The 
observed inconsistencies in practice in these particular studies make usual care difficult to 
understand and describe, therefore limiting its value as a comparator arm in the trial. Thompson and 
Schoenfeld suggested the use of a strict protocol and computer-aided decision support to improve 
both usual care and intervention group, but also rationalise that this itself might hinder the natural 
process, adaptation and change of usual care [38]. In light of this intricate debate, when dealing with 
complex interventions, we should consider the possible trial of two or more versions of a particular 
intervention. These versions may differ in one key component, which if absent, does not impinge on 
the coherency of the intervention but may allow identification of specific elements that impact upon 
efficacy and quality. Another consideration was raised by Gurjal and colleagues [31], where it was 
deduced that their medication adherence intervention was not tailored enough to measure 
improvements in individual patient outcomes. Potentially interventions cannot be “broadly” 
protocolled but must be adapted at an individual level and outcomes measured equally on a specific 
basis. Furthermore, Holland and colleagues [29] hypothesised that the negative effect of their 
intervention, i.e. increased primary care use, may have been due to their intervention being too late 
in a disease course to evoke a change in behaviour. This further supports the argument that 
interventions should be carefully designed, tailored and delivered to respond to specific population 
needs. 
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Strengths and weaknesses of the study 
Our search strategy included key databases and was supplemented by reviewing the references of 
relevant studies, review articles and conducting a citation search of identified studies. Where 
insufficient information was included in studies, authors were contacted. Our inclusion criteria were 
wide enough to capture any intervention made by a community pharmacist at the primary-
secondary care interface and did not exclude on the specifics of the populations, the interventions or 
outcomes reported. It became clear from our early literature search that the role of pharmacists, not 
specifically community pharmacists, is one that offers much potential to improve the transfer of 
patient care. Many studies reported on interventions solely performed by clinical pharmacists, 
hospital-based pharmacists or a liaison pharmacist that was not necessarily based in community, all 
of which were excluded in this review. This offers another perspective to investigate the particular 
characteristics, location and profile of a pharmacist that is a prerequisite of a ‘successful’ 
intervention. Our main focus was to concentrate on evaluating controlled studies only; we recognise 
this as a rigorous method for determining whether a cause-effect relation exists between 
intervention and outcome. However, in our systematic review, it was clear that much research exists 
of a qualitative and uncontrolled nature which could highlight some valuable lessons in the design 
and implementation of the interventions. The Medical Research Council has described that an 
evaluation of a complex intervention, which these transfer of care interventions can generally be 
considered to be, must include the investigation of how the intervention works. A more descriptive 
analysis of the context would facilitate the identification of the key active ingredients of an 
intervention, allowing for a better understanding of the causal mechanisms [39]. Hence, a process 
evaluation should complement an evaluation of effectiveness of any complex intervention. 
Unfortunately, due to the heterogeneous nature of the patient populations tested, the baseline risk 
and opportunity to impact on outcomes may have differed amongst trials, as patients may have 
been in receipt of varying types of care provision from other sources within the healthcare system. 
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This was keenly referred to in the intervention evaluations reported by Stafford and colleagues, 
where “warfarinised” patients, even in the control group received a contact visit with a GP eight 
days after discharge that could have shared components of monitoring, counselling, or medicines 
management information similar to that of the pharmacist intervention [25, 26]. Bellone and 
colleagues also listed one of their limitations as not considering other provider interventions taking 
place at the same time that could also possibly contribute to the hospital readmission rates [35]. 
Also the variation in patient groups between studies, including age, comorbidities, etc., may have 
made them more or less vulnerable to poor outcomes, therefore affecting the impact potential of 
the evaluated intervention. For example, the randomisation of patients between the control and 
intervention group in one study resulted in significantly more white patients on fewer medications 
and fewer diseases designated to the control group. All of these factors reflect a population that 
would be less likely to be rehospitalised [35]. Unstandardized delivery of the interventions, violations 
in protocols across providing pharmacies, and between individual pharmacists and even between 
patients from the same pharmacists, may have veiled beneficial effects in certain situations. 
As reported in a previous review [1] that focussed on any interventions made by any primary care 
providers at hospital discharge, we found that the intensity in intervention (number of interactions 
with the community pharmacist) did not appear to correlate directly to the effectiveness of the 
intervention. This reflects upon the complexity of factors to consider in the design and 
implementation of a ‘successful’ intervention. The evaluation of the qualitative and uncontrolled 
studies may shed further light onto the context and the interplay of patient, pharmacist and non-
pharmacist issues and in turn the design of future interventions.  
Findings in comparison with other studies 
This is the only review we are aware of that focusses on interventions involving community 
pharmacists made to improve the continuity of patient care PD from hospital. Unfortunately, before 
now there has been little pooled evidence around community pharmacist-led interventions. The 
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findings do agree in essence with related evaluations of interventions in the transfer of patients 
between primary and secondary care.  A recent systematic review of patient handovers from 
secondary to primary care at discharge by Hesselink and colleagues [1] describes that most 
interventions focussed on the sharing of discharge information, facilitation of continuity of care, and 
direct and timely communication between healthcare providers. The authors also deduced that no 
singular intervention was evidenced to guarantee positive effects on specific outcome measures. 
There was an acknowledgement that their review, in common with this review, evaluates complex 
interventions, including the number of interactions between components, the un-standardised 
delivery and receipt of interventions, the variability in targeting of the interventions, the number 
and diversity of outcomes and the degree of flexibility or tailoring of intervention components. It 
therefore becomes very problematic to isolate the fundamental role of any player or characteristic 
of that intervention [40]. This remains an issue despite the majority of the studies being classed as 
clear or very clear in their assessment for clarity of reporting against the CONSORT statement.  
Another review, that specifically looked at medication reviews in older patients as an intervention to 
reduce hospital readmissions, reported how variations in the delivery of care and patient selection 
hindered the ability to recommend consistent benefit from such interventions [41]. Okumura and 
colleagues [42] also concluded that the poor description of the counselling interventions evaluated 
in their review weakened their critique and subsequent evidence to support patient counselling as a 
robust intervention to improve patient outcomes. They advocated that clinical pharmacy services 
should adopt a systematic tool, e.g. DEPICT: Descriptive Elements of Pharmacist Interventions 
Characterisation Tool [40], to allow better understanding of the service and its components to 
ensure reproducibility and standardisation of delivery. Also, if a process evaluation is nested in a trial 
it can be used to assess fidelity and quality of implementation, clarify causal mechanisms and 
identify contextual factors associated with variation in outcomes [39].   
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Conclusion 
This review provides evidence to support the role of community pharmacists in identifying and 
rectifying medication errors post discharge, as part of interventions aiming to improve the transfer 
of care. However, insufficient data and flawed study design and implementation mean that further 
impact on patient outcomes cannot be deduced. To demonstrate consistent benefit more studies 
are required which are stricter in their intervention and usual care arms. Clear delineation will 
facilitate causal relationships to be better explored. Studies should also include process evaluations 
as standard so that contextual factors can be accounted for. These research modifications will 
improve the evidence base to inform future interventions and potentially describe the facilitative 
accompanying environment required to successfully improve continuity of care. 
Our findings are important at a time when many community pharmacies in the UK are responding to 
the recent RPS guidance to improve transfer of care. Until now MURs and NMS are services accessed 
by discharged patients, despite the lack of empirical robust data to support their potential in 
improving continuity of care. Although medicine related outcomes have here been evidenced, 
community pharmacy has yet to provide convincing verification of the impact on a range of 
economic, clinical and humanistic outcomes. If other interventions, excluding community pharmacy, 
are able to robustly demonstrate such collective effects on the continuity of care, the clinical 
qualities and role of community pharmacy in patient care will not be fully realised and possibly 
ignored. It is important that we recognise how more work needs to be done in this important area.  
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o
ri
n
g 
an
d
 t
ar
ge
te
d
 w
ar
fa
ri
n
 e
d
u
ca
ti
o
n
, r
ef
e
rr
al
s 
to
 G
P
 w
h
er
e
 n
ec
es
sa
ry
. 
H
o
sp
it
al
 
p
h
ar
m
ac
y,
 C
P
, 
G
P
 

  

  

  
N
az
ar
et
h
 
2
0
0
1
 [
3
3
] 
H
o
sp
it
al
 p
h
ar
m
ac
is
t 
as
se
ss
e
d
 m
e
d
ic
at
io
n
, r
at
io
n
al
is
at
io
n
 o
f 
tr
ea
tm
en
t,
 a
ss
e
ss
m
e
n
t 
o
f 
p
at
ie
n
t’
s 
ab
ili
ty
 t
o
 
m
an
ag
e 
th
ei
r 
m
e
d
ic
at
io
n
, p
ro
vi
si
o
n
 o
f 
d
ru
g 
in
fo
rm
at
io
n
 a
n
d
 li
ai
so
n
 w
it
h
 c
ar
er
s 
an
d
 c
o
m
m
u
n
it
y 
p
ro
fe
ss
io
n
al
s.
 
D
is
ch
ar
ge
 p
la
n
 w
as
 g
iv
en
 t
o
 p
at
ie
n
t 
an
d
 C
P
 a
n
d
 G
P
 a
n
d
 a
n
y 
o
th
er
 r
el
ev
an
t 
h
ea
lt
h
ca
re
 p
ro
fe
ss
io
n
al
 in
vo
lv
ed
. 
C
P
 m
ad
e 
h
o
m
e 
vi
si
t 
7
-1
4
 d
ay
s 
P
D
 t
o
 c
h
ec
k 
d
is
cr
ep
an
ci
es
 w
it
h
 m
ed
ic
at
io
n
 b
ei
n
g 
ta
ke
n
 a
n
d
 t
h
o
se
 p
re
sc
ri
b
e
d
. 
C
P
 a
ss
es
se
d
 p
at
ie
n
t’
s 
u
n
d
er
st
an
d
in
g 
o
f 
an
d
 a
d
h
er
en
ce
 t
o
 r
eg
im
en
 a
n
d
 in
te
rv
e
n
ed
 w
h
er
e 
ap
p
ro
p
ri
at
e.
 C
P
s 
ar
ra
n
ge
d
 f
u
rt
h
er
 v
is
it
s 
at
 t
h
ei
r 
o
w
n
 d
is
cr
et
io
n
. 
H
o
sp
it
al
 
p
h
ar
m
ac
is
t,
 C
P
, 
G
P
, o
th
er
 
h
ea
lt
h
ca
re
 
p
ro
fe
ss
io
n
al
s 

  

  

  
B
el
lo
n
e 
2
0
1
2
 
[3
5
] 
A
 C
P
 v
is
it
 w
it
h
in
 6
0
 d
ay
s 
P
D
 t
h
at
 c
o
u
ld
 h
av
e 
in
cl
u
d
e
d
 a
 n
u
m
b
er
 o
f 
in
te
rv
e
n
ti
o
n
s:
 d
is
co
n
ti
n
u
at
io
n
/i
n
it
ia
ti
o
n
 o
f 
d
ru
g 
th
er
ap
y,
 d
o
sa
ge
 a
d
ju
st
m
e
n
ts
, m
ed
ic
at
io
n
 c
o
u
n
se
lli
n
g,
 a
d
h
er
e
n
ce
 c
o
u
n
se
lli
n
g 
an
d
 la
b
o
ra
to
ry
 
m
o
n
it
o
ri
n
g.
 
C
P
 
 
 
 
B
ea
ch
es
n
e 
2
0
0
7
 [
3
7
] 
M
ed
ic
at
io
n
 h
is
to
ry
 c
ar
ri
e
d
 o
u
t 
b
y 
cl
in
ic
al
 p
h
ar
m
ac
is
t 
an
d
 c
o
m
m
u
n
ic
at
ed
 in
fo
rm
at
io
n
 w
it
h
 C
P
. O
n
 d
is
ch
ar
ge
 
cl
in
ic
al
 p
h
ar
m
ac
is
t 
co
u
n
se
ls
 o
n
 d
is
ch
ar
ge
 m
e
d
ic
at
io
n
 a
n
d
 c
o
m
p
le
te
s 
a 
d
is
ch
ar
ge
 p
la
n
 in
cl
u
d
in
g 
ad
m
is
si
o
n
 
d
ia
gn
o
si
s,
 c
o
m
o
rb
id
it
ie
s,
 a
lle
rg
ie
s/
d
ru
g 
in
to
le
ra
n
ce
s,
 m
e
d
ic
at
io
n
s 
p
re
-a
d
m
is
si
o
n
, c
h
an
ge
s 
m
ad
e 
an
d
 c
o
n
ta
ct
 
d
et
ai
ls
 o
f 
h
o
sp
it
al
 p
h
ar
m
ac
is
t.
 In
 in
te
rv
e
n
ti
o
n
 g
ro
u
p
 a
d
d
it
io
n
al
ly
 a
 li
st
 o
f 
3
 D
R
P
s 
w
it
h
 p
ro
p
o
se
d
 a
ct
io
n
s 
to
 
re
so
lv
e 
th
em
 w
er
e 
in
cl
u
d
e
d
 a
n
d
 C
P
 w
as
 p
h
o
n
ed
 a
n
d
 f
ax
e
d
 in
fo
rm
at
io
n
. 
H
o
sp
it
al
 
p
h
ar
m
ac
y,
 C
P
 

  

  

  
H
u
te
n
b
er
g 
2
0
0
9
 [
2
7
] 
U
su
al
 c
ar
e 
in
cl
u
d
ed
 f
ax
 o
f 
d
is
ch
ar
ge
 p
re
sc
ri
p
ti
o
n
 t
o
 C
P
, a
ls
o
 n
ew
ly
 p
re
sc
ri
b
ed
 d
ru
gs
 a
re
 a
cc
o
m
p
an
ie
d
 w
it
h
 
p
er
so
n
al
is
e
d
 le
tt
er
s 
o
f 
in
fo
rm
at
io
n
, a
n
d
 p
at
ie
n
ts
 r
ec
ei
ve
 a
d
d
it
io
n
al
 o
ra
l i
n
fo
rm
at
io
n
. T
h
e 
in
te
rv
en
ti
o
n
 a
d
d
e
d
 
in
 a
 c
h
ec
k 
b
y 
C
P
 o
f 
d
ru
gs
 p
re
- 
an
d
 p
o
st
-h
o
sp
it
al
is
at
io
n
 a
n
d
 d
if
fe
re
n
ce
s 
w
er
e 
re
co
rd
ed
 a
n
d
 a
y 
su
b
se
q
u
e
n
t 
in
te
rv
e
n
ti
o
n
 m
ad
e 
as
 a
 c
o
n
se
q
u
e
n
ce
. O
th
er
 in
te
rv
e
n
ti
o
n
s 
in
cl
u
d
ed
 t
ak
in
g 
a 
m
e
d
ic
at
io
n
 p
as
sp
o
rt
, p
ro
d
u
ci
n
g 
a 
d
ai
ly
 m
ed
ic
at
io
n
 s
ch
em
e,
 s
en
d
in
g 
th
es
e 
to
 p
at
ie
n
t 
an
d
 G
P
, s
yn
ch
ro
n
is
in
g 
d
is
ch
ar
ge
 a
n
d
 c
o
n
co
m
it
an
t 
m
ed
ic
at
io
n
 o
n
 t
im
e,
 in
te
rv
ie
w
in
g 
p
at
ie
n
t 
an
d
 c
h
ec
ki
n
g 
h
o
m
e 
d
ru
g 
su
p
p
lie
s.
 In
te
rv
en
ti
o
n
s 
w
er
e 
n
o
t 
st
an
d
ar
d
is
ed
. 
H
o
sp
it
al
 
p
h
ar
m
ac
y,
 C
P
, 
G
P
 

  

  

  
H
u
te
n
b
er
g 
2
0
1
2
 [
3
4
] 
C
P
 p
er
fo
rm
ed
 a
 m
ed
ic
at
io
n
 r
ev
ie
w
 a
t 
d
is
ch
ar
ge
, a
ft
er
 3
, 6
 a
n
d
 9
 m
o
n
th
s 
P
D
. 
C
P
, p
h
ar
m
ac
y 
te
ch
n
ic
ia
n
s 
an
d
 
n
o
t 
cl
ea
r 
w
h
o
 
el
se
 
 

  
 
H
o
lla
n
d
 2
0
0
5
 
[3
2
] 
D
is
ch
ar
ge
 le
tt
er
 s
e
n
t 
to
 C
P
. C
P
 a
rr
an
ge
d
 h
o
m
e 
vi
si
ts
 t
o
 a
ss
e
ss
 p
at
ie
n
t’
s 
ab
ili
ty
 t
o
 s
el
f-
m
e
d
ic
at
e 
an
d
 d
ru
g 
ad
h
er
en
ce
. E
d
u
ca
te
d
 p
at
ie
n
t 
an
d
 p
ro
xi
es
, r
em
o
ve
d
 o
u
t 
o
f 
d
at
e 
d
ru
gs
, r
e
p
o
rt
ed
 A
D
R
 o
r 
in
te
ra
ct
io
n
s 
to
 G
P
, 
an
d
 r
e
p
o
rt
ed
 n
ee
d
 f
o
r 
co
m
p
lia
n
ce
 a
id
 t
o
 lo
ca
l p
h
ar
m
ac
y.
 O
n
e 
fo
llo
w
-u
p
 v
is
it
 a
t 
6
-8
 w
ee
ks
 P
D
 t
o
 r
ev
ie
w
 a
n
d
 
re
in
fo
rc
e 
o
ri
gi
n
al
 a
d
vi
ce
.  
H
o
sp
it
al
, C
P
, G
P
 

  

  

  
This article is protected by copyright. All rights reserved. 
H
o
lla
n
d
 2
0
0
7
 
[2
9
] 
P
ac
in
i 2
0
0
7
 
[2
8
] 
C
P
 m
ad
e 
h
o
m
e 
vi
si
t 
w
it
h
in
 2
 w
ee
ks
 P
D
 t
o
 p
ro
vi
d
e 
p
at
ie
n
t 
m
e
d
ic
at
io
n
 e
d
u
ca
ti
o
n
 a
n
d
 li
fe
st
yl
e 
ad
vi
ce
. P
at
ie
n
ts
 
al
so
 c
o
m
p
le
te
d
 a
 s
ig
n
 a
n
d
 s
ym
p
to
m
 m
o
n
it
o
ri
n
g 
d
ia
ry
 c
ar
d
. R
ec
o
m
m
en
d
at
io
n
s 
w
er
e 
fe
d
 b
ac
k 
to
 G
P
. O
n
e 
fo
llo
w
-u
p
 v
is
it
 a
t 
6
-8
 w
ee
ks
 P
D
 t
o
 r
ev
ie
w
 a
n
d
 r
ei
n
fo
rc
e 
o
ri
gi
n
al
 a
d
vi
ce
.  
C
P
 
 

  

  
G
u
rj
al
 2
0
1
4
 
[3
1
] 
C
P
 r
ev
ie
w
ed
 p
at
ie
n
t 
m
o
n
th
ly
 t
o
 a
ss
es
s 
if
 m
ed
ic
at
io
n
 w
as
 b
ei
n
g 
co
lle
ct
ed
 a
n
d
 r
ec
o
rd
 a
n
y 
D
R
P
. A
T 
3
 a
n
d
 6
 
m
o
n
th
s 
P
D
 lo
n
ge
r 
d
is
cu
ss
io
n
s 
w
e
re
 t
ai
lo
re
d
 t
o
 m
e
d
ic
at
io
n
 b
e
lie
fs
 in
fo
rm
ed
 b
y 
re
se
ar
ch
er
. C
P
 f
u
n
d
e
d
 
R
es
ea
rc
h
er
, C
P
 
 
 
 
C
al
ve
rt
 2
0
1
2
 
[3
6
] 
A
t 
d
is
ch
ar
ge
 s
ta
n
d
ar
d
is
ed
 a
d
h
er
e
n
ce
 c
o
u
n
se
lli
n
g 
fr
o
m
 s
tu
d
y 
p
h
ar
m
ac
is
t 
an
d
 m
e
d
ic
at
io
n
 r
ev
ie
w
. P
ro
vi
d
ed
 a
 
p
o
ck
et
 m
ed
ic
at
io
n
 c
ar
d
, a
 li
st
 o
f 
ti
p
s 
fo
r 
re
m
em
b
er
in
g 
to
 t
ak
e 
m
e
d
ic
at
io
n
s 
an
d
 p
ill
b
o
x.
 F
ax
 o
f 
m
ed
ic
at
io
n
, 
an
d
 b
ar
ri
er
s 
to
 a
d
h
er
e
n
ce
 s
en
t 
to
 C
P
. S
tu
d
y 
p
h
ar
m
ac
is
t 
ca
lle
d
 p
at
ie
n
t 
1
-2
 w
ee
ks
 P
D
 t
o
 c
o
n
fi
rm
 c
o
lle
ct
io
n
 o
f 
m
ed
ic
at
io
n
. C
P
 v
er
if
ie
d
 a
d
h
er
e
n
ce
 im
m
ed
ia
te
ly
 a
n
d
 6
, 1
2
, 1
8
 a
n
d
 2
4
 w
ee
ks
 P
D
. W
h
en
 m
e
d
ic
at
io
n
 s
to
p
p
ed
 o
r 
m
is
se
d
 o
r 
an
y 
in
te
rv
en
ti
o
n
 w
as
 s
en
t 
to
 s
tu
d
y 
p
h
ar
m
ac
is
t 
an
d
/o
r 
G
P
. C
P
 f
u
n
d
ed
. 
St
u
d
y 
p
h
ar
m
ac
is
t,
 C
P
. 

  

  

  
C
ro
tt
y 
2
0
0
4
 
[3
0
] 
O
n
 h
o
sp
it
al
 d
is
ch
ar
ge
 t
o
 lo
n
g 
te
rm
 f
ac
ili
ty
, p
h
ys
ic
ia
n
 a
n
d
 C
P
 f
ax
e
d
 a
 m
ed
ic
at
io
n
 t
ra
n
sf
er
 s
u
m
m
ar
y 
co
m
p
ile
d
 
b
y 
tr
an
si
ti
o
n
 p
h
ar
m
ac
is
t 
(T
P
).
 T
P
 o
rg
an
is
e
d
 m
ed
ic
at
io
n
 r
ev
ie
w
 b
y 
C
P
 w
it
h
in
 1
0
-1
4
 d
ay
s 
P
D
, a
n
d
 a
 c
as
e 
co
n
fe
re
n
ce
 in
vo
lv
in
g 
h
im
/h
er
, t
h
e 
C
P
, p
h
ys
ic
ia
n
 a
n
d
 n
u
rs
e 
at
 t
h
e 
fa
ci
lit
y 
w
it
h
 1
4
-2
8
 d
ay
s 
P
D
. 
TP
, C
P
, 
p
h
ys
ic
ia
n
, n
u
rs
e
 

  

  

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Ta
b
le
 4
. T
h
e 
ty
p
es
 o
f 
o
u
tc
o
m
e
s 
an
d
 s
ta
ti
st
ic
al
 s
ig
n
if
ic
an
ce
 o
f 
e
ff
ec
ts
 b
y 
st
u
d
ie
d
 in
te
rv
en
ti
o
n
s.
((
+)
 O
u
tc
o
m
e 
w
it
h
 s
ta
ti
st
ic
al
ly
 s
ig
n
if
ic
an
t 
ef
fe
ct
 in
 f
av
o
u
r 
o
f 
th
e 
in
te
rv
e
n
ti
o
n
, 
(-
) 
o
u
tc
o
m
e 
w
it
h
 s
ta
ti
st
ic
al
ly
 s
ig
n
if
ic
an
t 
ef
fe
ct
 in
 f
av
o
u
r 
o
f 
th
e 
co
n
tr
o
l, 
an
d
 (
+∏
) 
o
u
tc
o
m
e 
w
it
h
 s
ta
ti
st
ic
al
ly
 s
ig
n
if
ic
an
t 
ef
fe
ct
 in
 f
av
o
u
r 
o
f 
a 
su
b
gr
o
u
p
 in
 t
h
e 
in
te
rv
en
ti
o
n
 a
rm
).
 
St
u
d
y,
 Y
e
ar
 
[R
e
f]
 
O
u
tc
o
m
e
 
H
o
sp
it
a
l u
se
 
Id
e
n
ti
fi
ca
ti
o
n
 
(n
o
. a
n
d
 t
yp
e
) 
o
f 
D
R
P
 
R
e
ct
if
ic
at
io
n
 
(n
o
. a
n
d
 t
yp
e
) 
o
f 
D
R
P
 
M
e
d
ic
at
io
n
 
ad
h
e
re
n
ce
 
P
at
ie
n
t 
kn
o
w
le
d
ge
 
P
at
ie
n
t 
sa
ti
sf
ac
ti
o
n
 
D
e
at
h
 
Q
u
al
it
y 
o
f 
lif
e
 
Q
u
al
it
y 
o
f 
p
re
sc
ri
b
in
g 
C
lin
ic
al
 
ad
ve
rs
e
 
e
ff
e
ct
s 
C
o
n
d
it
io
n
 
co
n
tr
o
l 
Ec
o
n
o
m
ic
 
e
va
lu
at
io
n
 
D
u
gg
an
 1
9
9
8
 
[1
9
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
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N
az
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
  
 
 

  

  

  

  

  
 
 
 
 
B
el
lo
n
e 
2
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2
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] 
   
   
   
   
   
   

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B
ea
ch
es
n
e 
2
0
0
7
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3
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] 
 

 (
+)
 

 (
+)
 

  
 
 
 
 
 
 
 
 
H
u
te
n
b
er
g 
2
0
0
9
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2
7
] 
 

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+)
 

 (
+)
 
 
 

 (
+)
 

  
 
 
 
 

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
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H
o
lla
n
d
 2
0
0
5
 
[3
2
] 

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
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
 (
−)
 
 
 

  
 

  

  

  
 
 
 
 
P
ac
in
i 2
0
0
7
 
[2
8
] 
 
 
 
 
 
 
 
 
 
 
 

  
G
u
rj
al
 2
0
1
4
 
[3
1
] 
 
 
 

  
 
 
 
 
 
 
 
 
C
al
ve
rt
 2
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1
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 Ta
b
le
 5
. S
p
ec
if
ic
 li
m
it
at
io
n
s 
o
f 
th
e 
in
cl
u
d
ed
 s
tu
d
ie
s 
th
at
 m
ay
 h
av
e 
in
fl
u
en
ce
d
 o
b
se
rv
ed
 o
u
tc
o
m
es
 
St
u
d
y,
 Y
e
ar
 
[R
e
f]
 
R
e
co
gn
is
e
d
 li
m
it
at
io
n
s 
o
f 
th
e
 s
tu
d
y 
D
u
gg
an
 1
9
9
8
 
[1
9
] 
N
o
n
-E
n
gl
is
h
 s
p
ea
ki
n
g 
p
at
ie
n
ts
 w
er
e 
e
xc
lu
d
ed
 f
ro
m
 t
h
e 
st
u
d
y 
w
h
ic
h
 m
ay
 h
av
e 
ca
u
se
d
 a
 r
ed
u
ct
io
n
 in
 t
h
e 
m
ag
n
it
u
d
e 
o
f 
th
e 
im
p
ac
t 
o
f 
th
e 
in
te
rv
e
n
ti
o
n
, s
in
ce
 la
n
gu
ag
e 
d
if
fi
cu
lt
ie
s 
m
ay
 h
av
e 
in
cr
ea
se
d
 t
h
e 
d
if
fe
re
n
ce
 b
et
w
ee
n
 t
h
e 
st
u
d
y 
ar
m
s.
 
A
 c
o
n
se
n
su
s 
m
et
h
o
d
o
lo
gy
 w
as
 u
se
d
 t
o
 c
la
ss
if
y 
th
e 
cl
in
ic
al
 s
ig
n
if
ic
an
ce
 o
f 
u
n
in
te
n
ti
o
n
al
 d
is
cr
ep
an
ci
e
s 
b
y 
th
e 
vi
ew
p
o
in
t 
o
f 
o
n
e 
p
an
el
 w
h
ic
h
 m
ay
 n
o
t 
h
av
e 
al
lo
w
ed
 e
xp
lo
ra
ti
o
n
 o
f 
b
re
ad
th
 
o
f 
ju
d
ge
m
en
t.
 
A
 la
ck
 o
f 
su
ff
ic
ie
n
t 
in
fo
rm
at
io
n
 a
b
o
u
t 
ea
ch
 in
d
iv
id
u
al
 t
o
 d
ef
in
e 
d
is
cr
ep
an
ci
e
s 
m
o
re
 a
cc
u
ra
te
ly
 a
s 
h
av
in
g 
a 
p
o
ss
ib
le
 a
d
ve
rs
e 
ef
fe
ct
 o
n
 t
h
e 
p
at
ie
n
t 
m
ay
 h
av
e 
re
su
lt
e
d
 in
 a
n
 u
n
d
er
e
st
im
at
io
n
 
o
f 
th
e 
n
u
m
b
er
 o
f 
se
ri
o
u
s 
d
is
cr
ep
an
ci
es
. 
 S
ta
ff
o
rd
 
2
0
1
1
 [
2
5
] 
R
ep
o
rt
in
g 
o
f 
d
ru
g 
re
la
te
d
 p
ro
b
le
m
s 
m
ay
 h
av
e 
b
ee
n
 lo
w
er
 t
h
an
 e
xp
ec
te
d
 s
in
ce
 p
o
te
n
ti
al
ly
 h
az
ar
d
o
u
s 
w
ar
fa
ri
n
 d
ru
g 
in
te
ra
ct
io
n
s 
m
ay
 h
av
e 
n
o
t 
n
ec
e
ss
it
at
ed
 a
tt
e
n
ti
o
n
 if
, f
o
r 
ex
am
p
le
, 
re
gu
la
r 
m
o
n
it
o
ri
n
g 
w
as
 t
ak
in
g 
p
la
ce
 o
r 
th
at
 t
h
e 
co
m
b
in
at
io
n
 h
ad
 b
ee
n
 t
ak
e
n
 f
o
r 
a 
p
er
io
d
 o
f 
ti
m
e 
w
it
h
 n
o
 a
d
ve
rs
e 
ef
fe
ct
s.
 In
 s
o
m
e 
ca
se
s 
so
m
e 
d
ru
g 
co
m
b
in
at
io
n
s 
ar
e 
cl
in
ic
al
ly
 ju
st
if
ie
d
, 
e.
g.
 w
ar
fa
ri
n
 a
n
d
 a
n
 a
n
ti
p
la
te
le
t 
in
 a
 p
at
ie
n
t 
w
it
h
 a
tr
ia
l f
ib
ri
lli
at
io
n
. 
D
at
a 
w
as
 a
n
al
ys
ed
 f
ro
m
 r
e
p
o
rt
s 
co
n
d
u
ct
ed
 b
y 
a 
sm
al
l n
u
m
b
er
 o
f 
ac
cr
ed
it
ed
 p
h
ar
m
ac
is
ts
 a
n
d
 t
h
er
ef
o
re
 m
ay
 n
o
t 
re
p
re
se
n
t 
a 
w
id
er
 r
o
ll 
o
u
t 
o
f 
th
e 
in
te
rv
en
ti
o
n
. 
Id
en
ti
fi
ca
ti
o
n
 o
f 
d
ru
g 
re
la
te
d
 p
ro
b
el
em
s 
w
as
 o
n
ly
 p
o
ss
ib
le
 f
ro
m
 w
h
at
 w
as
 r
ep
o
rt
e
d
 in
 t
h
e 
H
o
m
e 
M
ed
ic
in
es
 R
ev
ie
w
. 
D
ru
g 
re
la
te
d
 p
ro
b
le
m
s 
th
at
 w
er
e 
re
so
lv
ed
 w
it
h
o
u
t 
th
e 
re
q
u
ir
em
en
t 
fo
r 
p
re
sc
ri
b
er
 in
vo
lv
em
e
n
t 
m
ay
 n
o
t 
h
av
e 
b
e
en
 d
o
cu
m
e
n
te
d
. 
So
m
e 
p
h
ar
m
ac
is
ts
 m
ay
 h
av
e 
u
se
d
 c
lin
ic
al
 d
ec
is
is
o
n
 s
u
p
p
o
rt
 s
sy
st
e
m
s 
w
it
h
in
 t
h
e 
re
vi
ew
s 
an
d
 r
ep
o
rt
s 
an
d
 t
h
is
 w
as
 n
o
t 
re
co
rd
ed
. 
Th
es
e 
su
p
p
o
rt
 s
ys
te
m
s 
m
ay
 h
av
e 
ai
d
e
d
 d
ru
g 
in
te
ra
ct
io
n
 
id
en
ti
fi
ca
ti
o
n
. 
Sh
o
rt
-t
er
m
 m
e
d
ic
at
io
n
s,
 s
u
ch
 a
s 
an
ti
b
io
ti
cs
, w
er
e 
ex
cl
u
d
e
d
 f
ro
m
 t
h
e 
d
ru
g 
in
te
ra
ct
io
n
 li
st
 d
es
p
it
e 
th
ei
r 
p
o
te
n
ti
al
 t
o
 in
te
ra
ct
 w
it
h
 w
ar
fa
ri
n
. 
St
af
fo
rd
 2
0
1
2
 
[2
6
] 
Th
e 
m
et
h
o
d
o
lo
gy
 d
id
 n
o
t 
al
lo
w
 f
o
r 
as
se
ss
m
e
n
t 
o
f 
w
ar
fa
ri
n
 k
n
o
w
le
d
ge
 in
 t
h
e 
p
o
p
u
la
ti
o
n
 a
ss
ig
n
ed
 t
o
 t
h
e
 u
su
al
 c
ar
e 
ar
m
 a
t 
2
-3
 d
ay
s 
P
D
. I
t 
w
as
 d
ec
id
ed
 t
h
at
 if
 a
 v
is
it
 h
ad
 t
ak
en
 p
la
ce
 a
t 
th
is
 p
o
in
t 
it
 m
ay
 h
av
e 
le
d
 t
o
 p
at
ie
n
ts
 b
ei
n
g 
m
o
ti
va
te
d
 t
o
 s
el
f-
ed
u
ca
te
 a
n
d
 le
ad
 t
o
 c
o
n
fo
u
n
d
in
g 
o
f 
st
u
d
y 
re
su
lt
s.
 T
h
e
re
fo
re
 im
p
ro
ve
m
e
n
t 
in
 k
n
o
w
le
d
ge
 in
 t
h
e 
in
te
rv
en
ti
o
n
 g
ro
u
p
 c
an
n
o
t 
b
e 
u
n
eq
u
iv
o
ca
lly
 e
xp
la
in
ed
 b
y 
th
e 
h
o
m
e
-b
as
e
d
 w
ar
fa
ri
n
-e
d
u
ca
ti
o
n
. 
Th
e 
sa
m
p
le
 s
iz
e 
w
as
 s
m
al
l a
n
d
 r
e
st
ri
ct
ed
 in
 g
eo
gr
ap
h
ic
al
 a
re
a 
fr
o
m
 w
h
ic
h
 p
at
ie
n
ts
 w
er
e 
in
cl
u
d
ed
. 
Th
e 
O
A
K
 t
es
t 
fo
r 
as
se
ss
in
g 
p
at
ie
n
t 
kn
o
w
le
d
ge
 p
o
ss
e
ss
e
s 
so
m
e 
in
h
er
en
t 
lim
it
at
io
n
s 
su
ch
 a
s 
re
q
u
ir
in
g 
se
ve
n
th
 g
ra
d
e 
re
ad
in
g 
le
ve
l.
 
Im
p
ro
ve
m
en
t 
in
 p
at
ie
n
t 
kn
o
w
le
d
ge
 w
as
 s
h
o
rt
-l
iv
ed
 w
it
h
 r
eg
re
ss
io
n
 w
it
h
in
 3
 m
o
n
th
s.
 P
at
ie
n
ts
 m
ay
 h
av
e 
co
n
fo
u
n
d
e
d
 r
es
u
lt
s 
w
it
h
 f
am
ili
ar
it
y 
w
it
h
 t
h
e 
O
A
K
 t
e
st
 o
r 
th
e 
h
ig
h
er
 r
at
e 
o
f 
lo
ss
 t
o
 
fo
llo
w
-u
p
 in
 t
h
e 
in
te
rv
en
ti
o
n
 g
ro
u
p
 m
ay
 h
av
e 
m
ea
n
t 
th
at
 ‘n
o
n
-r
es
p
o
n
d
er
s’
 m
ay
 h
av
e 
ex
h
ib
it
ed
 d
if
fe
re
n
ce
s 
in
 w
ar
fa
ri
n
 k
n
o
w
le
d
ge
 
N
az
ar
et
h
 
2
0
0
1
 [
3
3
] 
B
as
el
in
e 
ad
h
er
en
ce
 w
as
 a
lr
ea
d
y 
h
ig
h
 w
it
h
in
 t
h
e 
st
u
d
y 
p
o
p
u
la
ti
o
n
 le
av
in
g 
lit
tl
e 
ro
o
m
 f
o
r 
im
p
ro
ve
m
en
t.
 D
at
a 
re
la
ti
n
g 
to
 p
at
ie
n
t 
kn
o
w
le
d
ge
 a
n
d
 a
d
h
er
e
n
ce
 w
as
 li
m
it
e
d
 s
in
ce
 in
fo
rm
at
io
n
 
w
as
 c
o
lle
ct
ed
 o
n
ly
 f
ro
m
 t
h
o
se
 w
it
h
o
u
t 
co
gn
it
iv
e 
im
p
ai
rm
e
n
t.
 
Th
e 
d
el
iv
er
y 
o
f 
th
e 
in
te
rv
e
n
ti
o
n
 w
as
 n
o
t 
st
an
d
ar
d
is
e
d
 o
r 
id
e
n
ti
ca
l a
m
o
n
gs
t 
th
e 
st
u
d
y 
p
o
p
u
la
ti
o
n
. 
B
el
lo
n
e 
2
0
1
2
 
[3
5
] 
Th
is
 w
as
 a
 s
m
al
l r
et
ro
sp
ec
ti
ve
 r
e
vi
ew
 b
as
ed
 o
n
e 
p
at
ie
n
ts
 o
n
ly
 a
d
m
it
te
d
 t
o
 o
n
e 
ac
u
te
 c
ar
e 
fa
ci
lit
y 
an
d
 d
o
es
 n
o
t 
ac
co
u
n
t 
fo
r 
ad
m
is
si
o
n
s 
o
r 
re
ad
m
is
si
o
n
s 
to
 o
th
er
 f
ac
il
it
ie
s.
 
Ex
te
rn
al
 p
ro
vi
d
er
 in
te
rv
en
ti
o
n
s 
w
er
e 
n
o
t 
co
n
si
d
er
e
d
 t
h
at
 c
o
u
ld
 h
av
e 
co
n
tr
ib
u
te
d
 t
o
 p
o
si
ti
ve
 o
u
tc
o
m
es
 r
eg
ar
d
in
g 
h
o
sp
it
al
 r
ea
d
m
is
si
o
n
s.
 
B
as
el
in
e 
ch
ar
ac
te
ri
st
ic
s 
o
f 
th
e 
p
o
p
u
la
ti
o
n
s 
in
 t
h
e 
st
u
d
y 
ar
m
s 
d
if
fe
re
d
 s
ig
n
if
ic
an
tl
y.
 
Sp
ec
if
ic
 in
fo
rm
at
io
n
 r
el
at
in
g 
to
 s
p
ec
if
ic
 d
is
ea
se
, c
la
ss
es
 o
f 
m
ed
ic
at
io
n
s 
an
d
 r
ea
so
n
s 
fo
r 
re
fe
rr
al
s 
w
as
 n
o
t 
co
lle
ct
ed
 t
o
 id
e
n
ti
fy
 w
h
er
e
 p
h
ar
m
ac
is
ts
 c
o
u
ld
 m
ak
e 
a 
m
o
re
 s
ig
n
if
ic
an
t 
im
p
ac
t.
 
Sp
ec
if
ic
 d
es
cr
ip
ti
o
n
s 
o
f 
th
e 
in
te
rv
en
ti
o
n
 p
er
fo
rm
ed
 b
y 
p
h
ar
m
ac
is
ts
 w
er
e 
ab
se
n
t 
an
d
 m
ay
 a
ga
in
 h
av
e
 d
em
o
n
st
ra
te
d
 im
p
o
rt
an
t 
el
em
en
ts
 o
f 
an
 in
te
rv
en
ti
o
n
. 
N
u
m
b
e
r 
o
f 
ad
ve
rs
e 
ev
en
ts
 w
as
 n
o
t 
co
lle
ct
ed
 t
o
 in
ve
st
ig
at
e 
co
rr
el
at
io
n
 t
o
 r
ea
d
m
is
si
o
n
s.
 
B
ea
ch
es
n
e 
2
0
0
7
 [
3
7
] 
Th
is
 w
as
 a
 s
m
al
l p
ilo
t 
st
u
d
y 
an
d
 in
cl
u
d
e
d
 o
n
ly
 a
 s
h
o
rt
 p
er
io
d
 o
f 
ti
m
e 
to
 f
o
llo
w
-u
p
.  
P
at
ie
n
ts
 in
 t
h
e 
in
te
rv
en
ti
o
n
 g
ro
u
p
 w
er
e 
aw
ar
e 
th
at
 t
h
ei
r 
C
P
 h
ad
 a
 li
st
 o
f 
u
n
re
so
lv
ed
 d
ru
g 
re
la
te
d
 p
ro
b
le
m
s 
th
at
 r
eq
u
ir
e
d
 in
te
rv
en
ti
o
n
s 
w
h
ic
h
 m
ay
 h
av
e 
m
o
ti
va
te
d
 p
h
ar
m
ac
is
ts
 t
o
 
This article is protected by copyright. All rights reserved. 
in
te
rv
e
n
e 
m
o
re
 f
re
q
u
e
n
tl
y.
 
A
d
h
er
en
ce
 w
as
 m
ea
su
re
d
 u
si
n
g 
a 
n
o
n
-v
al
id
at
e
d
 s
im
p
le
 t
o
o
l t
h
at
 t
e
n
d
s 
to
 o
ve
re
st
im
at
e 
ad
h
er
e
n
ce
. A
ls
o
 a
d
h
er
en
ce
 w
as
 a
ss
es
se
d
 a
t 
6
 w
ee
ks
 P
D
 w
h
ic
h
 is
 c
o
n
si
d
er
ed
 a
 s
h
o
rt
 p
er
io
d
 o
f 
ti
m
e 
to
 a
cc
u
ra
te
ly
 m
ea
su
re
. 
B
o
th
 in
te
rv
e
n
ti
o
n
 a
n
d
 c
o
n
tr
o
l g
ro
u
p
 p
at
ie
n
ts
 r
ec
ei
ve
d
 w
ri
tt
en
 d
is
ch
ar
ge
 p
la
n
s 
w
h
ic
h
 c
o
u
ld
 h
av
e 
e
xp
la
in
e
d
 h
ig
h
 c
o
n
co
rd
an
ce
 in
 b
o
th
 g
ro
u
p
s.
 
H
u
te
n
b
er
g 
2
0
0
9
 [
2
7
] 
P
ar
ti
ci
p
at
in
g 
p
h
ar
m
ac
is
ts
 w
er
e 
n
o
t 
ra
n
d
o
m
is
ed
. T
h
o
se
 d
ec
id
in
g 
to
 p
ar
ti
ci
p
at
e 
in
 t
h
e 
in
te
rv
e
n
ti
o
n
 g
ro
u
p
 m
ay
 h
av
e 
d
if
fe
re
d
 f
ro
m
 t
h
e 
co
n
tr
o
l g
ro
u
p
. 
C
h
an
ge
s 
m
ad
e 
to
 d
ru
g 
th
er
ap
y 
b
y 
a 
p
h
ar
m
ac
is
t 
h
av
e 
n
o
t 
b
ee
n
 c
h
ec
ke
d
 t
o
 a
ss
e
ss
 f
o
r 
an
 im
p
ro
ve
m
en
t 
in
 t
h
e 
ap
p
ro
p
ri
at
en
es
s 
o
f 
d
ru
gs
 d
is
p
e
n
se
d
. 
R
ea
so
n
s 
fo
r 
d
ru
g 
ch
an
ge
s 
w
er
e 
n
o
t 
co
lle
ct
ed
. 
In
fo
rm
at
io
n
 o
n
 r
eh
o
sp
it
al
is
at
io
n
s 
an
d
 d
ru
g 
re
la
te
d
 p
ro
b
le
m
s 
w
er
e 
n
o
t 
re
co
rd
ed
. 
N
o
t 
al
l i
n
te
rv
en
ti
o
n
 a
ct
iv
it
ie
s 
w
er
e 
fu
lly
 im
p
le
m
e
n
te
d
 b
y 
th
e 
p
h
ar
m
ac
is
ts
. 
Th
e 
m
ed
ic
at
io
n
 r
ev
ie
w
 c
ar
ri
ed
 o
u
t 
b
y 
p
h
ar
m
ac
is
ts
 w
as
 u
n
st
ru
ct
u
re
d
, a
n
d
 p
h
ar
m
ac
is
ts
 w
er
e 
n
o
t 
sp
ec
if
ic
al
ly
 t
ra
in
e
d
 f
o
r 
th
is
 t
as
k.
 
H
u
te
n
b
er
g 
2
0
1
2
 [
3
4
] 
In
su
ff
ic
ie
n
t 
d
et
ai
l p
ro
vi
d
ed
 t
o
 a
ss
es
s 
lim
it
at
io
n
s 
ac
cu
ra
te
ly
. 
In
te
rv
ie
w
s 
b
y 
p
h
ar
m
ac
y 
te
ch
n
ic
ia
n
s 
in
 b
o
th
 c
o
n
tr
o
l a
n
d
 in
te
rv
en
ti
o
n
 p
o
p
u
la
ti
o
n
s 
m
ay
 h
av
e 
in
cr
ea
se
d
 a
w
ar
en
e
ss
 o
f 
p
at
ie
n
ts
 t
o
 p
o
te
n
ti
al
 d
ru
g 
re
la
te
d
 p
ro
b
le
m
s 
to
 q
u
er
y 
o
r 
ra
is
e 
w
it
h
 
th
ei
r 
C
P
. 
H
o
lla
n
d
 2
0
0
5
 
[3
2
] 
Th
e 
in
te
rv
en
ti
o
n
 m
ay
 h
av
e 
h
el
p
e
d
 p
at
ie
n
ts
 u
n
d
er
st
an
d
 t
h
ei
r 
co
n
d
it
io
n
s 
b
et
te
r.
 P
at
ie
n
ts
 m
ay
 h
av
e 
b
ee
n
 m
o
re
 a
w
ar
e 
o
f 
w
ar
n
in
g 
si
gn
s 
ea
rl
ie
r 
an
d
 in
cr
ea
se
d
 h
e
lp
 s
ee
ki
n
g 
b
eh
av
io
u
r 
to
 
re
su
lt
 in
 m
o
re
 p
ri
m
ar
y 
ca
re
 u
se
. 
Th
e 
in
te
rv
en
ti
o
n
 m
ay
 h
av
e 
re
su
lt
ed
 in
 b
et
te
r 
ad
h
er
e
n
ce
 t
o
 m
ed
ic
at
io
n
s 
an
d
 in
d
ir
ec
tl
y 
p
re
ci
p
it
at
ed
 ia
tr
o
ge
n
ic
 il
ln
es
s 
th
at
 m
ay
 p
re
vi
o
u
sl
y 
h
av
e 
b
ee
n
 a
vo
id
ed
. 
Th
e 
h
o
m
e 
vi
si
t 
w
it
h
 in
cr
ea
se
d
 c
o
n
ta
ct
 t
im
e 
w
it
h
 t
h
e 
p
at
ie
n
t 
m
ay
 h
av
e 
in
cr
ea
se
d
 c
o
m
p
le
xi
ty
 o
f 
ca
re
 r
es
u
lt
in
g 
in
 in
cr
ea
se
d
 a
n
xi
e
ty
, c
o
n
fu
si
o
n
 o
r 
d
e
p
en
d
en
ce
. 
O
th
er
w
is
e 
th
e 
tr
ia
l h
ad
 h
ig
h
 in
te
rn
al
 v
al
id
it
y.
  
H
o
lla
n
d
 2
0
0
7
 
[2
9
] 
P
ac
in
i 2
0
0
7
 
[2
8
] 
Th
e 
in
te
rv
en
ti
o
n
 m
ay
 h
av
e 
b
e
en
 t
o
o
 la
te
 in
 t
h
e 
co
u
rs
e 
o
f 
th
e 
d
is
e
as
e 
to
 b
ri
n
g 
ab
o
u
t 
b
eh
av
io
u
r 
ch
an
ge
. 
Th
e 
p
h
ar
m
ac
is
ts
 w
er
e 
n
o
t 
sp
ec
ia
lis
ts
 in
 t
h
e 
d
is
ea
se
, i
.e
. h
ea
rt
 f
ai
lu
re
, a
n
d
 h
ad
 li
m
it
e
d
 k
n
o
w
le
d
ge
 in
 s
p
ec
if
ic
 c
ar
e,
 e
.g
. t
it
ra
ti
n
g 
d
ru
gs
 s
u
ch
 a
s 
lo
w
 d
o
se
 β
-b
lo
ck
er
s.
  
G
u
rj
al
 2
0
1
4
 
[3
1
] 
Th
e 
in
te
rv
en
ti
o
n
 t
o
 im
p
ro
ve
 a
d
h
er
en
ce
 in
 a
n
 ‘a
d
h
er
e
n
ce
 f
ee
d
b
ac
k’
 lo
o
p
 d
id
 n
o
t 
in
cl
u
d
e 
o
r 
id
en
ti
fy
 r
ea
so
n
s 
fo
r 
n
o
n
-a
d
h
er
e
n
ce
 t
o
 a
llo
w
 p
h
ar
m
ac
is
ts
 t
o
 t
ac
kl
e 
th
e
se
 s
p
ec
if
ic
 is
su
es
. 
Th
er
ef
o
re
 t
h
e 
in
te
rv
en
ti
o
n
 w
as
 n
o
t 
ta
ilo
re
d
 s
p
ec
if
ic
al
ly
 t
o
 e
ac
h
 p
at
ie
n
t’
s 
n
ee
d
s.
 
Th
e 
sa
m
p
le
 in
cl
u
d
ed
 p
at
ie
n
ts
 w
h
o
 h
ad
 e
xp
er
ie
n
ce
d
 a
n
 M
I,
 f
o
cu
ss
in
g 
sp
ec
if
ic
al
ly
 o
n
 n
o
n
-a
d
h
er
en
t 
p
at
ie
n
ts
 w
it
h
in
 t
h
is
 p
o
p
u
la
ti
o
n
 m
ay
 h
av
e 
yi
el
d
ed
 d
if
fe
re
n
t 
re
su
lt
s.
 
Th
e 
co
n
tr
o
l g
ro
u
p
 w
er
e 
fo
llo
w
ed
 u
p
 e
ve
ry
 m
o
n
th
 b
y 
th
e 
sa
m
e 
C
P
 a
n
d
 m
o
re
 o
f 
th
is
 g
ro
u
p
 a
tt
e
n
d
ed
 a
 c
ar
d
ia
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Figure 1. Flowchart describing study selection and excluded studies 
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